ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1140

Gout Characteristics and Its Association with the Presence of Cardiovascular Disease: A Case-Control Study

Mariano Andrés1,2, Salvador López-Salguero1, Francisca Sivera3, Loreto Carmona4, Paloma Vela1,2 and Eliseo Pascual1,5, 1Sección de Reumatología, Hospital General Universitario de Alicante, Alicante, Spain, 2Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain, 3Sección de Reumatología, Hospital General Universitario de Elda., Elda, Spain, 4Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain, 5Emeritus Professor, Universidad Miguel Hernández, Elche, Spain

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: cardiovascular disease and gout

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Metabolic and Crystal Arthropathies Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Gout is an independent risk factor for any type of cardiovascular disease (CVD). The exact mechanism behind remains to be elucidated, but persistent crystal-related inflammation is presumed as a key factor. The aim of this study was to assess whether gout characteristics that may indicate a more severe disease and higher inflammatory load are associated with the presence of CVD.

Methods: Case-control study, performed at baseline of an inception cohort including consecutive crystal-proven gout patients seen at a rheumatology unit. Gout features (time since first attack, number of attacks, number of joints ever affected, pattern of presentation, tophi) were registered after interview and physical exam. Presence and duration of CVD (which included coronary heart disease, heart failure, stroke or peripheral artery disease) was registered after interview and records review. Those patients who have suffered from CVD prior to the onset of gout were excluded. Other cardiovascular risk factors, as well as clinical and laboratory variables, were also registered. Odds ratios with 95% confidence intervals (95%CI) for each gout feature were calculated between patients with and without CVD, using a multiple logistic regression model to adjust for confounders.

Results: The inception cohort includes 308 patients; 54 were excluded for this study because gout onset occurred after CVD, so finally 254 cases were analyzed. Mean age was 61.4 years (SD 13.9), being 225 (88.6%) men. Regarding gout, median duration was 5 years (IQR 1-12), median number of reported attacks was 5 (IQR 2-14) that had involved a median of 3 joints (IQR 2-5); presenting attack was monoarticular in 77.4% cases, oligoarticular in 16.7%, and polyarticular in 6%, and 58 patients (22.8%) showed tophi at enrolment. A total of 32 patients (12.6%) had suffered from CVD at enrolment. Table shows the results of logistic regression analysis: time since first attack and polyarticular presentation of gout both significantly associated with the presence of CVD, while other variables showed no association. After multivariate analysis, time since first attack persisted associated with CVD, while polyarticular involvement showed a trend towards signification.

Conclusion: Time since first attack and likely a polyarticular presentation, two variables that may estimate crystal and inflammatory load in gout patients, are independently associated with the presence of CVD, adding evidence to the role of persistent inflammation on its development.

Association between gout features and cardiovascular disease

Simple regression

Multiple regression

OR (95%CI)

p

aOR (95%CI)*

p

Time since first attack

1.07 (1.03-1.10)

<0.001

1.06 (1.02-1.11)

0.005

Number of attacks suffered

1.00 (0.99-1.00)

0.561

–

–

Number of ever involved joints

1.09 (0.96-1.22)

0.177

–

–

Joint pattern at presentation

i. Monoarticular

1.0 (ref)

–

1.0 (ref)

–

ii.Oligoarticular

2.30 (0.93-5.72)

0.073

1.71 (0.44-6.65)

0.440

iii.Polyarticular

3.56 (1.02-12.32)

0.045

5.33 (0.92-30.78)

0.061

Tophi

1.64 (0.73-3.69)

0.234

–

–

*aOR: adjusted OR for age, gender, hypertension, diabetes, dyslipidemia, smoking background, obesity, and renal failure.


Disclosure: M. Andrés, Grunenthal, 5; S. López-Salguero, None; F. Sivera, AstraZeneca, 5; L. Carmona, None; P. Vela, None; E. Pascual, AstraZeneca, 5,Grunenthal, 5.

To cite this abstract in AMA style:

Andrés M, López-Salguero S, Sivera F, Carmona L, Vela P, Pascual E. Gout Characteristics and Its Association with the Presence of Cardiovascular Disease: A Case-Control Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/gout-characteristics-and-its-association-with-the-presence-of-cardiovascular-disease-a-case-control-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/gout-characteristics-and-its-association-with-the-presence-of-cardiovascular-disease-a-case-control-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology